|1969||Creation of Sunkyong Fibers Ltd.|
Listed on the Korean stock exchange,
Merged with Sunkyong Chemical Fibers Ltd.
|1978||First developers of PET resins in Korea|
|1984||Establishment of R&D Centre|
|1985||Acquisition of a textile factory in Suwon|
Formation of SK CYTEC Ltd.
Acquisition of Samshin Pharma Ltd.
Foundation of Sunbo Pharma Ltd.
Renamed to Sunkyong Industries Ltd.
Construction of PTA/DMT plant Formation of Life Science R&D Centre
Development of PPS resins
|1990||Creation of Petrochemical R&D Centre Renamed Sunkyong Pharmaceuticals Ltd.|
Creation of SK Keris Ltd.
in Indonesia Development of the ginkgo extract preparation, - Genexin®
|1994||Development of the anti-arthritis patch,
Trast® and Development of polyester adhesives
Renamed SK chemicals Ltd.
Creation of SK NJC Ltd.
|1999||Development of SUNPLA®,
Korea’s first new drug (a 3rd-generation platinum complex anti-cancer agent)
Exporting OMED® to EU.
|2000||Formation of Huvis Ltd.|
Establishment of SK chemicals Qingdao Ltd. in China
Development of the high-performance PETG resin, SKYGREEN®
Development of Korea’s first natural drug,(JOINS®, an anti-arthritis agent)
Creation of SK Eurochem Ltd. in Poland.
Establishment of SK chemicals Suzhou Ltd. in China
Formation of SK Pharma Beijing Ltd. in China
Founding of SK Utis Ltd.
Merged SK Pharmaceuticals Ltd.
Creation of SK Petrochemical Ltd.
Merged Dong Shin Pharma Ltd.
Development of biodiesel production technology
Establishment of Ningbo SK Zhenbang Chemical Ltd.
Formation of SK chemicals Pharma Beijing Ltd.
- Shanghai Branch.
Development of the anti-impotence drug, Mvix®.
|2008||Founding of Guilin SK Zhongning Bio Ltd.
Creation of SK chemicals GmbH in Germany.
Acquisition of UB Care, a healthcare solutions provider. Licensing SID530,
korea’s1st anti-cancer medicine, to Europe
Formation of SK Syntec Ltd.
Creation of ST Green Energy Ltd. in Singapore
Development of environment-friendly transparent heat-resistant co-polyester ECOZEN®.
NBP601, Korea’s first bio-pharmaceutical drug is licensed.
ECOZEN® wins the Silver Prize in the “Korea Technology Awards “Top 10 New Korean Technologies”
Minister’s Award in “Bio Diesel National Green Technology Award”
SK NJC venture equity acquisition and merger,
Selected as the provider of vaccine production equipment for cell culture.
|2011||Ecozen - Ground-breaking ceremony for the Andong Vaccine Plant.
EcoLab awarded the Eco-friendly Architecture Certification(LEED Platinum Certification) and Korean
ECOZEN®, the world’s first eco-friendly heat-resistant transparent bio-copolyester – awarded US FDA
Awarded the Grand Prize(Green Management Division) in the Global Standard Management Awards.
Special CDP (Carbon Disclosure Project) Prize The launch of “Embix S®”, the world’s first film-type
NBP601, a hemophilia treatment, is named one of Korea’s Ten New Technologies and wins the Minister
of Knowledge Economy Award
SID710, the patch-type dementia treatment Exelon, goes to EU
ell culture influenza vaccine received approval for first clinical trial by IND
|2013||SK chemicals and Teijin Chemicals launch joint venture INITZ and begin constructing PPS facilities
Andong Plant certified by LEED
PCT is named one of Korea’s Ten New Technologies and wins the Minister of Knowledge Economy Award
|2014||Developed Sanofi Pasteur and the next generation’s pneumonia vaccine and concluded a supply contract
Acquired KGMP for L House
The Ansan plant is combined with S House. Initz concluded a contract for PPS supply and co-marketing.
Received the Grand Prize(Sustainable Management Division) in the Global Standard Management Awards
Acquired a permit for SKYCELLFLU®, Korea’s first cell-cultivated in#uenza vaccine, to come into the market Korea FDA
Ranked First in the Chemicals Sector Listed Under DJSI Korea (2015)
Marketing Authorization Applications for NBP601 (Hemophilia Treatment) with the FDA (US) and EMA (EU)
Blood Derivatives Subsidiary 'SK Plasma' Established
World's First in Marketing Authorization for Cell-Culture Flu Vaccine
SKYCellflu® Launched, South Korea's First Cell-Culture Flu Vaccine
Dongtan Molding Lab Relocated and Expanded
Korea's First High-Performance Secondary Battery Electrolyte Additive Developed
DMT Production Facilities Expanded (Cap-up)
SKYCellflu Quadrivalent Launched, World's First Quadrivalent Cell-Culture Flu Vaccine
First Ever Marketing Authorization in US/Canada for Afstyla, a New Korean Antihemophilic Bio Drug
First ever marketing authorization in Europe and Japan for Afstyla, a new Korean antihemophilic bio-drug
First application of PCT automotive connector in domestic large-scale mass production center
New PETG plant expansion/operation
Agreement with international organization PATH to develop next-generation pediatric enteritis vaccine
Obtained DNV GL classification for SKYFlex in wind power generation applications
Jang Yeong-sil Award received for IR52, a biocopolyester / ABS composite for automotive interior applications
Marketing authorization for shingles vaccine SKYZoster (first in Korea, second world-wide)
Holding company SK Discovery launched